98%
921
2 minutes
20
Objective: To compare the patient characteristics and long-term outcomes for those treated with and without systemic immunomodulatory therapy (IMT) for non-infectious uveitis (NIU).
Design: Retrospective cohort study.
Participants: All consecutive adults with NIU receiving care at 5 uveitis subspecialty tertiary care clinics between 2010 and 2021.
Methods: Clinical outcomes were evaluated on initial presentation and at the last available follow-up. The main outcome measures were baseline characteristics and final visual acuity.
Results: A total of 914 NIU patients (418 IMT, 496 non-IMT) with a median age of 51.0 years and 57.4% female were identified. Over half the patients had bilateral disease, with a significantly higher proportion of bilateral cases in the IMT group compared with the non-IMT group (p < 0.001). The IMT group was more likely to have chronic uveitis (p < 0.001), with a higher proportion of patients experiencing cataracts and cystoid macular edema (p < 0.001 for both). A significantly higher proportion of non-IMT patients had anterior uveitis and an idiopathic etiology (p < 0.001). Overall, visual acuity improved significantly from baseline to last follow-up in the entire cohort (p < 0.001), with a slightly better improvement in the IMT group. Multivariable linear regression analysis suggested that baseline visual acuity and panuveitis were significant predictors of final visual acuity (p < 0.001 for both).
Conclusions: NIU patients on IMT are often younger, suffer from bilateral and chronic uveitis, and are more likely to have ocular complications. Those in the non-IMT group are more likely to have anterior idiopathic NIU. Baseline visual acuity and panuveitis are the main predictors of final vision outcomes among patients with NIU.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcjo.2023.10.002 | DOI Listing |
Eye (Lond)
September 2025
Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.
Objective: To compare the effectiveness of intravitreal faricimab and aflibercept injections in patients with polypoidal choroidal vasculopathy (PCV).
Methods: This retrospective study analysed 111 treatment-naïve eyes (111 patients) with PCV who received intravitreal injections of either faricimab (30 eyes) or aflibercept (81 eyes). All patients were treated with three initial monthly loading injections.
Microsyst Nanoeng
September 2025
Department of Ophthalmology, Key Laboratory of Precision Medicine for Eye Diseases of Zhejiang Province, Center for Rehabilitation Medicine,, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 314408, China.
Retinal surgery is one of the most delicate and complex operations, which is close to or even beyond the physiological limitation of the human hand. Robots have demonstrated the ability to filter hand tremors and motion scaling which has a promising output in microsurgery. Here, we present a novel soft micron accuracy robot (SMAR) for retinal surgery and achieve a more precise and safer operation.
View Article and Find Full Text PDFJ Neural Eng
September 2025
Hansen Experimental Physics Laboratory, Stanford University, 452 Lomita Mall, Stanford, California, 94305, UNITED STATES.
Clinical trials of the photovoltaic subretinal prosthesis PRIMA demonstrated feasibility of prosthetic central vision with resolution matching its 100 μm pixel width. To improve prosthetic acuity further, pixel size should be decreased. However, there are multiple challenges, one of which is related to accommodating a compact shunt resistor within each pixel that discharges the electrodes between stimulation pulses and helps increase the contrast of the electric field pattern.
View Article and Find Full Text PDFRetina
September 2025
Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA.
Purpose: To report outcomes of suprachoroidal hemorrhage (SCH).
Methods: Retrospective non-randomized study of eyes with SCH from two sites (1/1/2013-12/31/2022). The primary outcome was the 6-month change in visual acuity (VA).
Retina
September 2025
Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada.
Purpose: To report reattachment rate (RR) of pars plana vitrectomy-suprachoroidal viscopexy (VIT-SCVEXY) for rhegmatogenous retinal detachment (RRD) repair. Additionally, this study compares the anatomic reattachment rate and functional outcomes of VIT-SCVEXY vs pars plana vitrectomy with traditional scleral buckle (PPV-SB) at postoperative month 3 and final follow-up.
Methods: A retrospective cohort study conducted at St.